Disease · MONDO_0002169
rectum adenocarcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. rectum adenocarcinoma. Diseases, record MONDO_0002169. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002169
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- adenocarcinoma - rectum, adenocarcinoma of rectum, adenocarcinoma of the rectum, rectal adenocarcinoma
- Open Targets
Drugs56
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RALTITREXED | CHEMBL225071 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| OXALIPLATIN | CHEMBL414804 | Small molecule | Phase 3 | ClinicalTrials.gov | 48 | 48 | 41 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 3 | ClinicalTrials.gov | 47 | 47 | 47 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 34 | 34 | 29 | Drugs and targets |
| LEUCOVORIN CALCIUM | CHEMBL1201138 | Small molecule | Phase 3 | ClinicalTrials.gov | 13 | 13 | 12 | Drugs and targets |
| LEUCOVORIN | CHEMBL1679 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 7 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| FOLINIC ACID | CHEMBL1232801 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 5 | Drugs and targets |
| CETUXIMAB | CHEMBL1201577 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| IRINOTECAN | CHEMBL481 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 5 | Drugs and targets |
1 to 10 of 56
See all 56 drugsTargets117
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDCD1 | Programmed cell death protein 1 | 10 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| TYMS | Thymidylate synthase | 4 | Thymidylate synthase inhibitor | Approval | https://conductscience.org/library/genes/7298 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 3 | Epidermal growth factor receptor erbB1 inhibitor | Phase 3 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 3 | Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 2 | Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 other | Phase 3 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 1 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| TOP1 | DNA topoisomerase 1 | 2 | DNA topoisomerase I inhibitor | Phase 3 | https://conductscience.org/library/genes/7150 | Drugs and targets |
| VEGFA | Vascular endothelial growth factor A, long form | 2 | Vascular endothelial growth factor A inhibitor | Phase 3 | https://conductscience.org/library/genes/7422 | Drugs and targets |
| ABL1 | Tyrosine-protein kinase ABL1 | 1 | Tyrosine-protein kinase ABL inhibitor | Phase 1 | https://conductscience.org/library/genes/25 | Drugs and targets |
| AKT1 | Serine/threonine-protein kinase AKT | 1 | Serine/threonine-protein kinase AKT inhibitor | Phase 2 | https://conductscience.org/library/genes/207 | Drugs and targets |
1 to 10 of 117
See all 117 targetsTrials86
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00265850 | Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | Phase 3 | 2,334 | 2017-04-26 | Colorectal Cancer | BEVACIZUMAB, CETUXIMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT02340949 | Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer | Phase 2 | 180 | 2021-05-03 | Rectal Cancer | AFLIBERCEPT, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00527111 | Pre-op Rectal ChemoRad +/- Cetuximab | Phase 2 | 139 | 2016-11-03 | Rectal Cancer | CETUXIMAB, FLUOROURACIL | Its record names the disease | ClinicalTrials.gov |
| NCT00114231 | Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer | Phase 2 | 90 | 2018-03-29 | Colorectal Cancer | CAPECITABINE, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT03904043 | Non-Operative Management and Early Response Assessment in Rectal Cancer | Not applicable | 63 | 2025-06-11 | Adenocarcinoma of the Lower Rectum | CAPECITABINE, FOLINIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT03259035 | NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer | Phase 2 | 58 | 2024-10-10 | Rectal Cancer | CAPECITABINE, FLUOROURACIL, FOLINIC ACID, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00001880 | Stem Cell Transplantation for Metastatic Solid Tumors | Phase 2 | 42 | 2021-11-10 | Neoplasm Metastasis | CYCLOSPORINE, METHOTREXATE | Its record names the disease | ClinicalTrials.gov |
| NCT02641691 | Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum | Phase 2 | 20 | 2021-02-18 | Cancer of Rectum, Cancer of the Rectum, Neoplasm, Rectum, Rectal Cancer, Rectum Cancer, Rectum Neoplasms, Adenocarcinoma of the Rectum | FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00625183 | Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma | Phase 2 | 5 | 2014-09-26 | Colorectal Cancer | CAPECITABINE, OXALIPLATIN, SELENOMETHIONINE | Its record names the disease | ClinicalTrials.gov |
| NCT03300544 | Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer | Phase 1 | 3 | 2024-05-01 | Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectal Adenocarcinoma, Stage III Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7 | CAPECITABINE, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN, TALIMOGENE LAHERPAREPVEC | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 86
See all 86 trialsComparisons in its trials9
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm A: FOLFOX or FOLFIRI + Bevacizumab vs Arm B: FOLFOX or FOLFIRI + Cetuximab: serious adverse events | 98 of 559 | 111 of 578 | 1,137 | NCT00265850 | Trial comparisons |
| mFOLFOX6 + Aflibercept vs mFOLFOX6: deaths from any cause | 12 of 115 | 7 of 65 | 180 | NCT02340949 | Trial comparisons |
| mFOLFOX6 + Aflibercept vs mFOLFOX6: serious adverse events | 45 of 115 | 16 of 65 | 180 | NCT02340949 | Trial comparisons |
| Chemoradiotherapy Plus Cetuximab vs Chemoradiotherapy Alone: serious adverse events | 10 of 67 | 5 of 62 | 129 | NCT00527111 | Trial comparisons |
| Original Dose Group vs Revised Dose Group: deaths from any cause | 0 of 57 | 0 of 27 | 84 | NCT00114231 | Trial comparisons |
| Original Dose Group vs Revised Dose Group: serious adverse events | 6 of 57 | 2 of 27 | 84 | NCT00114231 | Trial comparisons |
| Radiation + FOLFOX vs Radiation + CAPOX: deaths from any cause | 1 of 54 | 0 of 8 | 62 | NCT03904043 | Trial comparisons |
| Radiation + FOLFOX vs Radiation + CAPOX: serious adverse events | 21 of 54 | 2 of 8 | 62 | NCT03904043 | Trial comparisons |
| Radiation + FOLFOX vs Radiation + CAPOX: Clinical Complete Response Rate | 36 of 51 | 2 of 7 | 58 | NCT03904043 | Trial comparisons |
Papers from its trials111
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002169
GET https://conductscience.org/api/diseases/v1/MONDO_0002169/drugs?page=2